再発または難治性多発性骨髄腫患者を対象とした、レブリミド®5mgカプセルの実使用条件下での長期治療における安全性および有効性に関する研究

基本情報

NCT ID

NCT02922543

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

361

治験依頼者名

Celgene

概要

To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in patients with "relapsed or refractory multiple myeloma" (hereinafter referred to as "relapsed or refractory MM") who have received long-term treatment with it under the actual condition of use. 1. Planned registration period This period started on the date of initial marketing of Revlimid and will end at the time when the planned number of patients to be enrolled, 300, is reached (estimated to be approximately 1 year and 3 moths). 2. Planned surveillance period This period started on the date of initial marketing of Revlimid and will end 3 years after the last enrolled patient begins receiving Revlimid (estimated to be approximately 4 years and 3 months).

対象疾患

依頼者（Sponsor）

実施施設 (1)